TABLE: 2014 IPO values mixed at mid-year
This article was originally published in Scrip
Executive Summary
Going public isn't easy, even in a market that's receptive to biotechnology initial public offerings, but 41 drug developers made the leap in the US during the first half of 2014 and raised $2.6bn.
You may also be interested in...
Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré
Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.
Cerulean Slashes Jobs After Phase II Kidney Cancer Failure
Cerulean will cut its staff by almost half to reprioritize its remaining cash as it recovers from a clinical trial failure for its lead drug candidate that shifts the program's immediate focus from kidney to ovarian cancer.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.